| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella, Ferdinando Carlo Sass. Adapting the GLP-1-signaling system to the treatment of type 2 diabetes. Current diabetes reviews. vol 3. issue 1. 2008-03-11. PMID:18220652. |
multiple actions other than insulin secretion stimulation give to glp-1 a highly desirable profile for an antidiabetic agent. |
2008-03-11 |
2023-08-12 |
Not clear |
| Baptist Gallwit. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs of today (Barcelona, Spain : 1998). vol 43. issue 11. 2008-03-06. PMID:18174966. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip) are important incretin hormones contributing to 50-70% of the stimulation of insulin secretion after a meal. |
2008-03-06 |
2023-08-12 |
Not clear |
| Leonid E Fridlyand, Mark C Harbeck, Michael W Roe, Louis H Philipso. Regulation of cAMP dynamics by Ca2+ and G protein-coupled receptors in the pancreatic beta-cell: a computational approach. American journal of physiology. Cell physiology. vol 293. issue 6. 2008-03-04. PMID:17928534. |
incretin hormones such as glucagon-like peptide 1 (glp-1) increase camp and augment insulin secretion in pancreatic beta-cells. |
2008-03-04 |
2023-08-12 |
Not clear |
| Judith Korner, Marc Bessler, William Inabnet, Carmen Taveras, Jens Juul Hols. Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery. vol 3. issue 6. 2008-02-21. PMID:17936091. |
the aim of this study was to measure the circulating levels of glucagon-like peptide-1 (glp-1), glucose-dependent insulinotropic peptide (gip), and glucagon in patients who had undergone adjustable gastric banding (bnd) or roux-en-y gastric bypass (rygb) to understand the differences in glucose and insulin regulation after these procedures. |
2008-02-21 |
2023-08-12 |
Not clear |
| J E Milton, C S Sananthanan, M Patterson, M A Ghatei, S R Bloom, G S Fros. Glucagon-like peptide-1 (7-36) amide response to low versus high glycaemic index preloads in overweight subjects with and without type II diabetes mellitus. European journal of clinical nutrition. vol 61. issue 12. 2008-02-19. PMID:17299480. |
glucagon-like-peptide-1 (7-36) amide (glp-1) is an insulin secretagogue and potential treatment for type ii diabetes mellitus. |
2008-02-19 |
2023-08-12 |
human |
| David D'Alessio, Wendell Lu, William Sun, Shuqin Zheng, Qing Yang, Randy Seeley, Stephen C Woods, Patrick Ts. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. American journal of physiology. Regulatory, integrative and comparative physiology. vol 293. issue 6. 2008-02-15. PMID:17898126. |
glp-1 is released from mucosal l cells following nutrient ingestion and contributes to the incretin effect, with the enhancement of insulin secretion occurring with enteral compared with intravenous glucose administration. |
2008-02-15 |
2023-08-12 |
rat |
| David D'Alessio, Wendell Lu, William Sun, Shuqin Zheng, Qing Yang, Randy Seeley, Stephen C Woods, Patrick Ts. Fasting and postprandial concentrations of GLP-1 in intestinal lymph and portal plasma: evidence for selective release of GLP-1 in the lymph system. American journal of physiology. Regulatory, integrative and comparative physiology. vol 293. issue 6. 2008-02-15. PMID:17898126. |
lymph contained detectable concentrations of glucose, insulin, and glp-1 that were reliably measured using our assays. |
2008-02-15 |
2023-08-12 |
rat |
| Ken Fujiok. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. JAAPA : official journal of the American Academy of Physician Assistants. vol Suppl. 2008-02-14. PMID:18217245. |
the incretins are important gut mediators of insulin release, and in the case of glp-1, of glucagon suppression. |
2008-02-14 |
2023-08-12 |
Not clear |
| Maria Sörhede Winzell, Bo Ahré. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. Journal of molecular endocrinology. vol 40. issue 2. 2008-02-14. PMID:18234911. |
glucagon-like peptide 1 (glp-1) augments glucose-stimulated insulin secretion (gsis) through camp-induced activation of protein kinase a (pka), and stimulates beta-cell proliferation and reduces beta-cell apoptosis in rodent islets. |
2008-02-14 |
2023-08-12 |
mouse |
| Maria Sörhede Winzell, Bo Ahré. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. Journal of molecular endocrinology. vol 40. issue 2. 2008-02-14. PMID:18234911. |
this study explored islet gsis, pka expression, and markers of apoptosis (caspase 3/7 activity) and proliferation (pkbalpha and pancreatic and duodenal homeobox gene 1, pdx-1) after 2 weeks of treatment with the glp-1 receptor agonist exendin-4 (2 nmol/kg once daily) in female mice with high-fat diet-induced insulin resistance (hfd; 58% fat by energy). |
2008-02-14 |
2023-08-12 |
mouse |
| Jiaqi Chen, Gang Bai, Yu Cao, Zhihui Gao, Qi Zhang, Yuanyuan Zhu, Wenbo Yan. One-step purification of a fusion protein of glucagon-like peptide-1 and human serum albumin expressed in pichia pastoris by an immunomagnetic separation technique. Bioscience, biotechnology, and biochemistry. vol 71. issue 11. 2008-02-11. PMID:17986790. |
glucagon-like peptide-1 (glp-1) has great therapeutic potential to treat diabetes type 2, mainly due to its unique glucose-dependent stimulation of insulin secretion profiles, but its clinical application is limited by its short half-life in vivo, which resultes from degradation by dipeptidyl peptidase iv and/or renal clearance. |
2008-02-11 |
2023-08-12 |
mouse |
| Murielle Combettes, Catherine Karga. Newly approved and promising antidiabetic agents. Therapie. vol 62. issue 4. 2008-01-16. PMID:17983555. |
glp-1, also released in a post-prandial manner, promotes insulin production and secretion, reduces glucagon secretion, delays gastric emptying and induces a feeling of fullness. |
2008-01-16 |
2023-08-12 |
Not clear |
| Zhong Q Wang, Aamir R Zuberi, Xian H Zhang, Jacalyn Macgowan, Jianhua Qin, Xin Ye, Leslie Son, Qinglin Wu, Kun Lian, William T Cefal. Effects of dietary fibers on weight gain, carbohydrate metabolism, and gastric ghrelin gene expression in mice fed a high-fat diet. Metabolism: clinical and experimental. vol 56. issue 12. 2008-01-08. PMID:17998014. |
after baseline measurements were assessed for body weight, plasma insulin, glucose, leptin, and glucagon-like peptide 1 (glp-1), animals were treated for 12 weeks. |
2008-01-08 |
2023-08-12 |
mouse |
| Zhong Q Wang, Aamir R Zuberi, Xian H Zhang, Jacalyn Macgowan, Jianhua Qin, Xin Ye, Leslie Son, Qinglin Wu, Kun Lian, William T Cefal. Effects of dietary fibers on weight gain, carbohydrate metabolism, and gastric ghrelin gene expression in mice fed a high-fat diet. Metabolism: clinical and experimental. vol 56. issue 12. 2008-01-08. PMID:17998014. |
these results suggest differences in response to dietary fiber intake in this animal model because high-fat diets incorporating dietary fibers such as scf and psy appeared to attenuate weight gain, enhance insulin sensitivity, and modulate leptin and glp-1 secretion and gastric ghrelin gene expression. |
2008-01-08 |
2023-08-12 |
mouse |
| Attila Juhász, Evelin Katona, Eva Csongrádi, György Parag. [The regulation of body mass and its relation to the development of obesity]. Orvosi hetilap. vol 148. issue 39. 2007-12-21. PMID:17890170. |
body mass--strictly speaking: the adipose tissue mass--is regulated in a feed-back system by the hypothalamus and brainstem, where adiposity signals (leptin, insulin, amylin) and intestinal peptides (ghrelin, pyy, pp, glp-1, oxm, cck) and the vagal nerve provide afferent information to the central controller on the size of white adipose tissue and the actual nutritional state, respectively. |
2007-12-21 |
2023-08-12 |
Not clear |
| Subhash Kini, Daniel M Herron, Robert T Yanagisaw. Bariatric surgery for morbid obesity--a cure for metabolic syndrome? The Medical clinics of North America. vol 91. issue 6. 2007-12-20. PMID:17964919. |
the decrease in insulin resistance is because of significant weight loss and by enhancing secretion of gut hormones such as glucagon-like peptide-1 (glp-1). |
2007-12-20 |
2023-08-12 |
Not clear |
| Jianhua Hou, Ruixiang Yan, Dongfeng Ding, Liquan Yang, Cuiyan Wang, Zhiqiang Wu, Xiaoju Yu, Weidong Li, Minggang L. Oral administration of a fusion protein containing eight GLP-1 analogues produced in Escherichia coli BL21(DE3) in streptozotocin-induced diabetic rats. Biotechnology letters. vol 29. issue 10. 2007-12-13. PMID:17581704. |
glucagon-like peptide-1 (7-36) amide (glp-1), a gut hormone released into the blood stream after feeding, can stimulate insulin secretion by potentiating the insulinotropic action of glucose. |
2007-12-13 |
2023-08-12 |
rat |
| Carolyn F Deacon, Richard D Carr, Jens J Hols. DPP-4 inhibitor therapy: new directions in the treatment of type 2 diabetes. Frontiers in bioscience : a journal and virtual library. vol 13. 2007-12-11. PMID:17981667. |
one emerging area of interest is centred upon the actions of the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip), which enhance meal-induced insulin secretion and have trophic effects on the beta-cell. |
2007-12-11 |
2023-08-12 |
Not clear |
| A Barnet. Exenatide. Expert opinion on pharmacotherapy. vol 8. issue 15. 2007-12-06. PMID:17931093. |
it mirrors many of the effects of glp-1, improving glycaemic control through a combination of mechanisms, which include glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, slowing of gastric emptying and reduced appetite. |
2007-12-06 |
2023-08-12 |
Not clear |
| Nathalie M Delzenne, Patrice D Cani, Audrey M Neyrinc. Modulation of glucagon-like peptide 1 and energy metabolism by inulin and oligofructose: experimental data. The Journal of nutrition. vol 137. issue 11 Suppl. 2007-12-06. PMID:17951500. |
the chronic administration of glp-1 receptor antagonist exendin 9-39 totally prevents the beneficial effects of ofs (improved glucose tolerance, fasting blood glucose, glucose-stimulated insulin secretion, insulin-sensitive hepatic glucose production, and reduced body weight gain). |
2007-12-06 |
2023-08-12 |
mouse |